Eligibility criteria included age ≥18 years to ≤75 years; histologically confirmed cancer diagnosis; positivity for at least one HLA-A*02 inclusion allele; MAGE-A4 RNA or protein expression in one or more tumor samples; and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 before LD chemotherapy (see Methods for full inclusion criteria). The gene discussed is HLA-A; the disease is cancer.